HK1042241A1 - 膠囊系統 - Google Patents

膠囊系統 Download PDF

Info

Publication number
HK1042241A1
HK1042241A1 HK02103939.6A HK02103939A HK1042241A1 HK 1042241 A1 HK1042241 A1 HK 1042241A1 HK 02103939 A HK02103939 A HK 02103939A HK 1042241 A1 HK1042241 A1 HK 1042241A1
Authority
HK
Hong Kong
Prior art keywords
active agent
vehicle
gastrointestinal tract
emulsifier
capsule system
Prior art date
Application number
HK02103939.6A
Other languages
English (en)
Chinese (zh)
Inventor
A. Firestone Bruce
T. Tran Thao
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of HK1042241A1 publication Critical patent/HK1042241A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02103939.6A 1999-03-04 2000-03-03 膠囊系統 HK1042241A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/262,623 1999-03-04
US09/262,623 US6248354B1 (en) 1999-03-04 1999-03-04 Capsule system
PCT/US2000/005811 WO2000051571A2 (en) 1999-03-04 2000-03-03 Capsule system

Publications (1)

Publication Number Publication Date
HK1042241A1 true HK1042241A1 (zh) 2002-08-09

Family

ID=22998308

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103939.6A HK1042241A1 (zh) 1999-03-04 2000-03-03 膠囊系統

Country Status (7)

Country Link
US (3) US6248354B1 (enExample)
EP (1) EP1158965A2 (enExample)
JP (1) JP2002538098A (enExample)
AU (1) AU768796B2 (enExample)
CA (1) CA2363933C (enExample)
HK (1) HK1042241A1 (enExample)
WO (1) WO2000051571A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7115277B2 (en) * 1999-03-04 2006-10-03 Allergan, Inc. Method for enabling delivery of an active agent
US6457471B1 (en) 2000-06-30 2002-10-01 Medihale Ltd. Dual-purpose medical device for upper airway treatment and methods for using same
IL156411A0 (en) * 2000-12-15 2004-01-04 Franke Patrick Hypoallergenic and non-irritant skin care formulations
US6752953B2 (en) * 2001-12-03 2004-06-22 Yung Shin Pharmaceutical Co., Ltd. Method for manufacturing hard non-gelatin pharmaceutical capsules
WO2004017958A1 (ja) * 2002-08-20 2004-03-04 Nikken Chemicals Co., Ltd. 軟カプセル剤
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
AU2004261286A1 (en) * 2003-07-30 2005-02-10 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoid components
US20050026949A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoids without regard to body weight
US20050026950A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
US20050027003A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids with reduced side effects
US20060020037A1 (en) * 2004-07-22 2006-01-26 Allergan, Inc. Tazarotenic acid and esters thereof for treating autism
AU2006232344A1 (en) * 2005-04-04 2006-10-12 Archer-Daniels-Midland Company Lignan-containing compositions
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
KR101725196B1 (ko) * 2009-02-25 2017-04-10 스티펠 리서치 오스트레일리아 피티와이 리미티드 국소 폼 조성물
SG2014012173A (en) 2009-05-20 2014-07-30 Ranbaxy Lab Ltd Topical retinoid solutions
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
US20150150829A1 (en) * 2012-07-02 2015-06-04 Dsm Ip Assets B.V. Capsules containing thymoquinone
JP7728653B2 (ja) * 2021-04-05 2025-08-25 真 小林 内視鏡用処置具

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960M (fr) * 1962-03-30 1964-11-30 Pfizer & Co C Compositions, facilement dispersibles dans l'eau, a base d'ester d'acide gras de vitamine a.
JPS58128141A (ja) * 1982-01-26 1983-07-30 Sumitomo Chem Co Ltd 自己乳化分散型カロチノイド類含有ソフトカプセル剤の製法
US4612194A (en) 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
JPH0426670A (ja) * 1990-05-18 1992-01-29 Nisshin Flour Milling Co Ltd 安定化された油溶性ビタミン含有組成物
US5965160A (en) * 1995-04-24 1999-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system

Also Published As

Publication number Publication date
WO2000051571A3 (en) 2001-02-15
CA2363933A1 (en) 2000-09-08
WO2000051571A2 (en) 2000-09-08
AU3726600A (en) 2000-09-21
EP1158965A2 (en) 2001-12-05
AU768796B2 (en) 2004-01-08
JP2002538098A (ja) 2002-11-12
WO2000051571B1 (en) 2001-05-25
CA2363933C (en) 2006-07-11
US20010016206A1 (en) 2001-08-23
US6248354B1 (en) 2001-06-19
US20040115257A1 (en) 2004-06-17
US6656500B2 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
WO2000051571A3 (en) Capsule system
WO2002002085A3 (de) Schnell zerfallende darreichungsform zur freisetzung von wirkstoffen im mundraum oder in körperhöhlen
IE871584L (en) Sustained release capsule.
EP0374359A3 (en) Chewable, edible soft gelatin capsule
CA2168732A1 (en) Gelatin Capsules Containing a Highly Concentrated Acetaminophen Solution
CA2272586A1 (en) Rapidly disintegrable pharmaceutical composition
CA2337046A1 (en) Sustained release pharmaceutical preparation
EP0795324A3 (en) A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
CA2362728A1 (en) Improved aqueous solubility pharmaceutical formulations
CA2333869A1 (en) Mousse composition
WO2003017940A3 (en) Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
WO2003051304A3 (en) Bioadhesive drug delivery system with enhanced gastric retention
CA2365826A1 (en) Over-coated chewing gum formulations
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
GB9223144D0 (en) Controlled release device
HK1042444A1 (zh) 藥用噴霧製劑
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
NZ336691A (en) Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
CA2377916A1 (en) Taste masked pharmaceutical liquid formulations
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
HK1043948A1 (zh) 一種用於在體腔內傳遞流動液體的一次性器具
CA2420461A1 (en) Preparations for oral administration
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
CA2256751A1 (fr) Comprime enrobe a base de maleate de trimebutine